Here, the authors aimed to determine if cerebrospinal fluid levels of sSORLA in Alzheimer's disease patients carrying SORL1 rare variants that impact or not the trafficking of the protein can be used as a novel biomarker to explore disrupted trafficking of SorLA protein in Alzheimer's disease.
